Approximately 25% of the NF1 mutations co-occurred with mutations in known oncogenes: BRAF, ERBB2, KRAS, HRAS and NRAS. Therapeutic strategies targeting KRAS activation, including the use of inhibitors of MAP kinase signalling, may warrant investigation in NF1 mutant tumours. The gene discussed is KRAS; the disease is neoplasm.